Home Tags Antibody

Tag: antibody

Featured Image: Laboratory Glass works. Courtesy: © 2010 - 2018. Fotolia Used with permission.

Antibody-drug Conjugates: Intracellular Trafficking of New Anticancer Therapeutics

A new article, published by a team of writers including Muhammad Kalim, Jie Chen, and Shenghao Wang from the Department of Biochemistry and Genetics,...

A New Method to Generate Human Antibodies

Traditionally, the production of antibodies, considered the molecular workhorses of protein research, has been slow and complex. Less than a decade ago, generating research-grade...

Developing the Next Generation of Clinically Successful Antibody-drug Conjugates

Since the approval of the first antibody-drug conjugate or ADC, now more than 15 years ago, scientists and researchers have sent more than 50...

Compugen’s Antibody Drug Conjugate Program Results Presented

This week, during the World ADC Summit being held October 19 - 22, 2015 in San Diego, CA, Compugen presented the status of its predictive...

A Chemistry Driven Approach to Uniform Antibody-drug Conjugates: New Data on...

Earlier today, during a plenary session of the 2015 World ADC Summit, being held October 26-29, 2014 in San Diego, California, Randall Halcomb, PhD, Vice President Chemistry at Igenica Biotherapeutics, presented new data utilizing the company's SNAP site-specific ADC linker technology.

Sutro Collaborates with Merck and Recombinant Antibody Network

Earlier today, Sutro Biopharma, Inc, a biopharmaceutical company located in South San Francisco developing antibody drug conjugates and bispecific antibodies for targeted cancer therapies, and Merck Serono, the biopharmaceutical division of Merck KGaA (Darmstadt, Germany), the world’s oldest pharmaceutical and chemical company established in 1668 which operates as EMD Serono in the United States and Canada, announced that they will collaborate in developing Antibody-drug Conjugates or ADCs.

The Clinical Landscape of Antibody-drug Conjugates

Antibody drug conjugates (ADCs) are a class of therapeutics that combine the selective targeting properties of monoclonal antibodies (mAbs) with potent cell killing activities of cytotoxic agents. Given rapid pace of progress in this field, it is important for drug developers to have a high level view of the landscape of ADCs in the clinic. This review analyzes ADCs tested in the field of Oncology. Trials are evaluated by cancer type, trial status, phase, and characteristics of the ADC.
European Hematology Association

Preclinical Data of Novel Antibody-drug Conjugate IMGN779 Demonstrates Potent Activity Against...

Results from a preclinical trial shows that IMGN779, a novel, DNA-alkylating, anticancer therapeutics based on ImmunoGen, Inc, antibody-drug conjugates (ADC) technology, shows potent activity against CD33-expressing acute myeloid leukemia cells,including leukemic stem cells, while sparing normal cells.

Challenges and Strategies for the Downstream Processing of BiSpecific Antibodies (BsAbs)

Baeuerle and Raum present an extensive review of BsAbs in their article. [2] BsAbs are most commonly used for cancer immunotherapy where they are targeted to simultaneously bind to a cytotoxic cell as well as a target tumor cell to be destroyed. Targeting two antigens simultaneously can be a promising approach. This paper will include a review of the challenges associated with the manufacturing of BsAbs in mammalian cell cultures, and the strategies that can be implemented to overcome treatment challenges.
Memorial Sloan Kettering Research Building

Memorial Sloan-Kettering Agrees to Use New Technology for Neuroblastoma Research

Memorial Sloan-Kettering Cancer Center has agreed to use to Sutro Biopharma's proprietary cell-free protein synthesis technology to produce bispecific antibodies that were discovered in the center's clinic for the treatment of neuroblastoma in children.